Eli Lilly And Stock Net Income

LLY Stock  USD 778.18  3.28  0.42%   
Eli Lilly And fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Net Income is likely to drop to about 3.1 B in 2024. Net Income Applicable To Common Shares is likely to drop to about 4 B in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eli Net Income Analysis

Eli Lilly's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Eli Lilly Net Income

2.71 Billion

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Eli Lilly Net Income

    
  5.24 B  
Most of Eli Lilly's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly And is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Eli Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(4.54 Billion)

Eli Lilly reported Accumulated Other Comprehensive Income of (4.33 Billion) in 2023
Based on the recorded statements, Eli Lilly And reported net income of 5.24 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.

Eli Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.
Eli Lilly is currently under evaluation in net income category among related companies.

Eli Lilly ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Eli Lilly Institutional Holders

Institutional Holdings refers to the ownership stake in Eli Lilly that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eli Lilly's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eli Lilly's value.
Shares
Geode Capital Management, Llc2023-12-31
16 M
Morgan Stanley - Brokerage Accounts2023-12-31
12.7 M
Wellington Management Company Llp2023-12-31
11.8 M
Norges Bank2023-12-31
10.3 M
Bank Of America Corp2023-12-31
9.9 M
Goldman Sachs Group Inc2023-12-31
9.4 M
Northern Trust Corp2023-12-31
9.1 M
Jennison Associates Llc2023-12-31
7.6 M
Capital Research Global Investors2023-12-31
7.6 M
Lilly Endowment Inc2023-12-31
99.8 M
Vanguard Group Inc2023-12-31
71.6 M

Eli Fundamentals

About Eli Lilly Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Net Income5.2 B3.1 B
Net Income Applicable To Common Shares7.2 BB
Net Income From Continuing Ops5.2 B4.4 B
Net Income Per E B T 0.80  0.60 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Eli Lilly Piotroski F Score and Eli Lilly Altman Z Score analysis.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.81
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.